Cyclometallated ruthenium(II) carbonyl complexes with 1-pyrenaldehyde 4-R-3-thiosemicarbazones: Regioselective ruthenation of the 1-pyrenyl group

Palladium(ii) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors

New palladium complexes with thiosemicarbazonate ligands derived from pyrene exhibit potent antiproliferative activity against A2780 and cisplatin-resistant A2780Cis human ovarian cancer cells, which is dependent on substituent groups of the thiosemicarbazone ligands. Cellular accumulation and distribution studies confirmed that palladium enters the cell nucleus. DNA and topoisomerase IB studies show that one complex is a potent TopIB inhibitor, with selectivity for cancer versus normal cells.

Novel tetranuclear PdII and PtII anticancer complexes derived from pyrene thiosemicarbazones

Cyclometallated palladium(ii) and platinum(ii) pyrenyl-derived thiosemicarbazone (H₂PrR) complexes of the type [M₄(μ-S-PrR-κ³-C,N,S)₄] (M = Pd^II, Pt^II; R = ethyl, cyclohexyl) have been synthesised in good yields and fully characterised.

A Half-Sandwich Rhodium(III) Complex with 4-Bromo-N-(1-Pyrenylidene)Aniline: Regioselective Cyclorhodation of the 1-Pyrenyl Group

Reaction of [RhCp*Cl2]2 (Cp* = pentamethylcyclopentadienyl anion), 4-bromo-N-(1-pyrenylidene)aniline (Hpyan, H represents a proton of the 1-pyrenyl ring) and CH3CO2Na in 1:2:6 mole ratio in dichloromethane provides the half-sandwich, cyclometallated rhodium(III) complex [RhCp*(pyan)Cl]. X-ray crystallographic study confirms the bidentate 1-pyrenyl ortho-C and azomethine-N coordination mode of (pyan)−and the half-sandwich ‘piano-stool’ structure of [RhCp*(pyan)Cl]. In dichloromethane, the diamagnetic, redox active complex displays a metal-centred oxidation at E1/2 = 1.14 V (versus Ag/AgCl).